These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29124632)

  • 1. Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review.
    Ghijben P; Gu Y; Lancsar E; Zavarsek S
    Pharmacoeconomics; 2018 Mar; 36(3):323-340. PubMed ID: 29124632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.
    Linley WG; Hughes DA
    Pharmacoeconomics; 2013 Apr; 31(4):345-55. PubMed ID: 23516033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
    Williams I; McIver S; Moore D; Bryan S
    Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
    Andronis L; Barton P; Bryan S
    Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health technology assessment in Australia: a role for clinical registries?
    Scott AM
    Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.
    Guthrie S; Bienkowska-Gibbs T; Manville C; Pollitt A; Kirtley A; Wooding S
    Health Technol Assess; 2015 Aug; 19(67):1-291. PubMed ID: 26307643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
    Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
    Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
    Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
    BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia.
    Fischer KE; Heisser T; Stargardt T
    Health Policy; 2016 Oct; 120(10):1115-1122. PubMed ID: 27628196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
    MacLeod TE; Harris AH; Mahal A
    Patient; 2016 Jun; 9(3):201-22. PubMed ID: 26370257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
    Hashem F; Calnan MW; Brown PR
    Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
    Ball G; Levine MAH; Thabane L; Tarride JE
    Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Power relations and contrasting conceptions of evidence in patient-involvement processes used to inform health funding decisions in Australia.
    Lopes E; Carter D; Street J
    Soc Sci Med; 2015 Jun; 135():84-91. PubMed ID: 25950114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priority setting for health technology assessment at CADTH.
    Husereau D; Boucher M; Noorani H
    Int J Technol Assess Health Care; 2010 Jul; 26(3):341-7. PubMed ID: 20584365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
    Wong CKH; Wu O; Cheung BMY
    Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold.
    Griffiths EA; Hendrich JK; Stoddart SD; Walsh SC
    Clinicoecon Outcomes Res; 2015; 7():463-76. PubMed ID: 26366099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
    Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
    Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.